Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Imfinzi combo shows unprecedented survival in HCC

January 19, 2022

Enhertu granted Priority Review for breast cancer

January 17, 2022

AstraZeneca and Neurimmune sign deal for NI006

January 7, 2022

Transfer of rights to Eklira, Duaklir completed

January 5, 2022

AstraZeneca and Ionis close eplontersen deal

December 29, 2021

Ultomiris accepted for FDA Priority Review for gMG

December 21, 2021

Tezspire approved in the US for severe asthma

December 20, 2021

Saphnelo recommended for EU approval for SLE

December 20, 2021

Evusheld US FDA EUA

December 9, 2021

AstraZeneca, Ionis to collaborate on eplontersen

December 7, 2021

Lynparza granted FDA Priority Review for OlympiA

November 30, 2021

AZN: Year to date and Q3 2021 results

November 12, 2021

AstraZeneca to transfer rights to Eklira, Duaklir

November 1, 2021

Imfinzi improved survival in biliary tract cancer

October 25, 2021

AZ recommends ADS holders reject mini-tender offer

October 18, 2021

Imfinzi & tremelimumab improved OS in liver cancer

October 15, 2021

AZD7442 PhIII trial positive in COVID outpatients

October 11, 2021

Enhertu granted BTD for breast cancer

October 4, 2021

AstraZeneca to fully acquire Caelum Biosciences

September 29, 2021

Saphnelo approved in Japan for SLE

September 28, 2021

Lynparza PROpel trial meets primary endpoint

September 24, 2021

New Sustainability Committee of the Board

September 23, 2021

Board Committee Change

September 23, 2021

AstraZeneca $360m Irish manufacturing investment

September 21, 2021

Enhertu reduced risk of disease progression by 72%

September 20, 2021

Imfinzi improves survival in NSCLC in POSEIDON

September 9, 2021

PT027 PhIII asthma trials met primary endpoints

September 9, 2021

Ultomiris approved in EU for children with PNH

September 3, 2021

Forxiga approved in Japan for CKD

August 26, 2021

ALXN1840 Wilson Phase III met primary endpoint

August 26, 2021

Update on Ultomiris Phase III ALS trial

August 20, 2021

AZD7442 prophylaxis trial met primary endpoint

August 20, 2021

Update on US review of roxadustat

August 11, 2021

Forxiga approved in the EU for CKD

August 9, 2021

Enhertu head-to-head trial meets primary endpoint

August 9, 2021

Saphnelo approved in the US for SLE

August 2, 2021

AZN: H1 2021 Results

July 29, 2021

Ultomiris recommended in EU for children with PNH

July 26, 2021

Acquisition of Alexion completed

July 21, 2021

Imfinzi approved in China for extensive-stage SCLC

July 19, 2021

Status on US FDA Advisory Committee for roxadustat

July 16, 2021

AstraZeneca-Alexion transaction cleared in the UK

July 14, 2021

Tezepelumab granted FDA Priority Review for asthma

July 8, 2021

AstraZeneca-Alexion transaction cleared in the EU

July 6, 2021

Forxiga recommended in EU for patients with CKD

June 28, 2021

Nirsevimab PhII/III trial confirms safety profile

June 28, 2021

Lynparza approved in China for prostate cancer

June 24, 2021

Orpathys approved in China for lung cancer

June 23, 2021

Koselugo approved in the EU for children with NF1

June 22, 2021

Update on AZD7442 STORM CHASER trial

June 15, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 249 decks. Every deck is listed under its year.